Last reviewed · How we verify
IBE-814 70ug — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
IBE-814 70ug (IBE-814 70ug) — Ripple Therapeutics Pty Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IBE-814 70ug TARGET | IBE-814 70ug | Ripple Therapeutics Pty Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IBE-814 70ug CI watch — RSS
- IBE-814 70ug CI watch — Atom
- IBE-814 70ug CI watch — JSON
- IBE-814 70ug alone — RSS
Cite this brief
Drug Landscape (2026). IBE-814 70ug — Competitive Intelligence Brief. https://druglandscape.com/ci/ibe-814-70ug. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing